8-K - Biofrontera Inc. (0001858685) (Filer)

S-8 - Biofrontera Inc. (0001858685) (Filer)

8-K - Biofrontera Inc. (0001858685) (Filer)

8-K - Biofrontera Inc. (0001858685) (Filer)

8-K - Biofrontera Inc. (0001858685) (Filer)

10-Q - Biofrontera Inc. (0001858685) (Filer)

8-K - Biofrontera Inc. (0001858685) (Filer)

8-K - Biofrontera Inc. (0001858685) (Filer)

8-K - Biofrontera Inc. (0001858685) (Filer)

8-K - Biofrontera Inc. (0001858685) (Filer)

Benchmark initiated coverage of Biofrontera with a rating of Buy and set a new price target of $11.00

Roth Capital initiated coverage of Biofrontera with a rating of Buy and set a new price target of $20.00

SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

SC 13G - Biofrontera Inc. (0001858685) (Subject)

SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

SC 13G - Biofrontera Inc. (0001858685) (Subject)

SC 13G - Biofrontera Inc. (0001858685) (Subject)

 ●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton.    ●Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or 5.6% as compared to the same period last year. Without the impact of Hurricane Milton delaying shipments, the increase would have been 12%.    ●Ameluz® achieved record volume in September 2024.      ●Organization continues to prudently manage SG&A expenses in line with business needs with a reduction of 14% in the first 9 months of 2024 vs 2023.    ●Cash and cash equivalents were $2.9 million as of September 30, 2

WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.Conference Call and Webcast InformationEvent:Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference CallDate:Thursday, November 14, 2024Time:10:00am ETConference Call:1-877-

First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant p<0.0001Correlates to data seen in Europe where sBCC is already incorporated in the Summary of Product Characteristics.BCC is the most common skin cancer in the US, with more than 3 million cases each year1. WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, today announced top-line results in its Phase 3 study of the use of Ameluz® with the BF-RhodoLED® lamp in the treatment of sBCC (study ALA-BCC-CT013)

First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions.Data now being analyzed, interim results expected November 2024.BCC is the most common skin cancer in the US with more than 3 million cases each year1. WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announced today that the database for the treatment phase of study ALA-BCC-CT013 has been locked. The database lock is an important milestone i

Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz®-PDT using the BF-RhodoLED or the RhodoLED XL lampSupplemental New Drug Application (sNDA) supported by two Phase 1 safety studiesAK is the second most common diagnosis made by dermatologists in the United States1An estimated 13 million treatments given each year for AK in the US2 WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's sNDA to increase t

WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that management will present at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Metropolitan Club in New York, NY.Date: October 9, 2024Time of Presentation: 12:30 - 1:10 PM ETFormat: Live Presentation1x1 Meetings: Please contact your Roth representativeAbout Biofrontera Inc.Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topi

Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months ended June 30, 2024 and provided a business update. Highlights from the second quarter of 2024 and subsequent weeks included the following: Total revenues for the second quarter of 2024 were $7.8 million, a 34% increase from the same period of the prior yearCash and cash equivalents were $4.4 million as of June 30, 2024, compared with $1.3 million on December 31, 2023Biofrontera announced the launch of a new, FDA-approved red-light sour

WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024. The results will be released after the market close on Wednesday, Aug 14 and the company will host a conference call on Thursday, August 15 at 10:00am Eastern Time.Conference Call and Webcast InformationEventBiofrontera Inc. Second Quarter 2024 Financial Results and Business Update Conference CallDateThursday, August 15, 2024Time10:00am ETConference Call1-877-877-1275 (U.S.)1-412-858-5202 (international)W

The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalpBiofrontera launched the commercial distribution of the RhodoLED XL on June 10, 2024, shipping the first three machines within 1 week of launch WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp. Biofrontera RhodoLED XL

Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2024 and provided a business update.Highlights from the first quarter of 2024 and subsequent weeks included the following:Total revenues for the first quarter of 2024 were $7.9 million, a 9% decrease from the same period of the prior year primarily driven by reimbursement headwinds our customers experienced due to the Change Healthcare data breachCash and cash equivalent

WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications. Biofrontera created this position in response to the growing demand and opportunity for specialized sales and marketing approaches resulting from an evolving landscape of medical practices consolidating into larger integrated organizations.Reporting to Mark Baldyga, Vice President of Sales and Marketing, Ms. Widdicombe joins Biofrontera with over

WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet brings to Biofrontera more than 20 years of commercial and scientific experience in the life sciences industry, along with proven success in developing high-growth technology companies.Dr. Lanckriet was nominated to Biofrontera Inc.'s Board of Directors by Biofrontera AG under the terms of the April 2023 settlement agreement between the two companies previously disclosed in the Company's Current Report o

Executive Chairman Hermann Luebbert to Assume CEO Responsibilities, Reaffirms the Company's Strategic Plan and 2023 Commercial GoalsWOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the resignation of Erica Monaco as Chief Executive Officer, which will be effective pending the completion of a near term transition of responsibilities with the Board of Directors. Hermann Luebbert, Biofrontera's Executive Chairman and founder, will assume the CEO responsibilities. Ms. Monaco intends to pursue other professional opportunities and her resignation did not res

WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the final voting results from its 2022 Annual Meeting of Stockholders held on December 12, 2022. Stockholders re-elected board nominee Loretta M. Wedge to the Biofrontera Inc. Board of Directors as Class I director to serve until the 2025 Annual Meeting of Stockholders.Stockholders approved an amendment to the Biofrontera Inc. 2021 Omnibus Incentive Plan to increase the number of shares authorized for issuance under the plan by 2,589,800 shares.Stockholders ratified the appointment of Grant Thornt

WOBURN, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Fred Leffler as Chief Financial Officer, effective immediately. Mr. Leffler is an experienced financial executive with 15 years of leadership, financial management, consultancy and operations experience across a range of private and public organizations, including growth-stage, private equity and Fortune 100 companies. Most recently, Mr. Leffler was a Senior Manager at McKinsey & Company in Boston, having served in a similar capacity in their Washington, D.C. office earlier in his career.

WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Gerard DiGirolamo as National Sales Director. In this newly created position, Mr. DiGirolamo will report to Mark Baldyga, Biofrontera's Head of Sales & Marketing, and will help execute the Company's U.S. sales division and objectives including the strategic design, expansion and leadership of its sales team. He will oversee recruiting and staffing to support Ameluz®, BF-RhodoLED® and Xepi® commercial efforts, as well as spearhead planning for the launch of BF-RhodoLED XL®. Mr. DiGirolamo

WOBURN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Kevin D. Weber to its Board of Directors, expanding Board membership to five Directors. Mr. Weber is an experienced pharmaceutical executive who brings to Biofrontera more than 30 years of executive and commercialization experience with a particular expertise in product marketing. He has worked in a range of therapeutic areas including clinical and aesthetic dermatology, pain management, inborn errors of metabolism and respiratory medicine. He is currently a Principal at

The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalpBiofrontera launched the commercial distribution of the RhodoLED XL on June 10, 2024, shipping the first three machines within 1 week of launchWOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp.

Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(2.88) per share which missed the analyst consensus estimate of $(1.17) by 146.15 percent. This is a 48.57 percent increase over losses of $(5.60) per share from the same period last year. The company reported quarterly sales of $7.912 million which missed the analyst consensus estimate of $10.857 million by 27.12 percent. This is a 9.40 percent decrease over sales of $8.733 million the same period last year.

Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d

Gainers Novavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Portage Biotech (NASDAQ:PRTG) stock increased by 57.97% to $0.41. The market value of their outstanding shares is at $8.1 million. ITeos Therapeutics (NASDAQ:ITOS) stock rose 46.92% to $17.91. The company's market cap stands at $644.1 million. As per the press release, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 37.87% to $5.25. The company's market cap stands at $86.1 million. As per the press release, Q1 earnings came out yesterday. Cardio Diag

Gainers Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 129.0% to $2.7 during Friday's pre-market session. The company's market cap stands at $7.1 million. Novavax (NASDAQ:NVAX) shares rose 119.23% to $9.8. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 51.18% to $5.76. The company's market cap stands at $94.4 million. As per the news, the Q1 earnings report came out yesterday. Natera (NASDAQ:NTRA) shares moved upwards by 20.31% to $114.96. The market value of their outstanding shares is at $14.0 billion. The company's, Q1 earnings came out yesterday. XTL Biopharmaceu

Gainers Kineta (NASDAQ:KA) shares increased by 24.3% to $0.67 during Monday's after-market session. The market value of their outstanding shares is at $7.3 million. Moleculin Biotech (NASDAQ:MBRX) stock increased by 10.21% to $5.6. The company's market cap stands at $12.4 million. Cue Health (NASDAQ:HLTH) stock moved upwards by 6.01% to $0.18. The market value of their outstanding shares is at $29.3 million. Nexalin Technology (NASDAQ:NXL) shares moved upwards by 5.57% to $2.46. The company's market cap stands at $18.2 million. Atara Biotherapeutics (NASDAQ:ATRA) stock moved upwards by 5.52% to $0.8. The market value of their outstanding shares is at $95.2 million. PetVivo Hldgs (NASDA

Shares of Jabil Inc. (NYSE:JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. Jabil posted adjusted earnings of $1.68 per share, beating estimates of $1.66 per share. The company’s quarterly sales came in at $6.77 billion, missing expectations of $6.89 billion. Jabil shares dipped 14.2% to $126.56 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Verb Technology Company, Inc. (NASDAQ:VERB) shares jumped 189% to $0.4047. VERB's MARKET.live launched Facebook and Instagram social shopping technology integration. Better Therapeutics, Inc. (NASDAQ:BTTX) surged 108

Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report quarterly loss at $0.10 per share on revenue of $7.83 million. • NeoGenomics (NASDAQ:NEO) is likely to report quarterly earnings at $0.17 per share on revenue of $182.13 million. • Prestige Consumer (NYSE:PBH) is estimated to report quarterly earnings at $1.20 per share on revenue of $1.61 billion. • Hibbett (NASDAQ:HIBB) is projected to report quarterly earnings at $2.55 per share on revenue of $477.49 million. • RLX Technology (NYSE:RLX) is expected to report quarterly earnings at $0.02 per share on revenue of $66.52 million. • KVH Industries (NASDAQ:KVHI) is expected to report quarterly loss at $0

4 - Biofrontera Inc. (0001858685) (Issuer)

4 - Biofrontera Inc. (0001858685) (Issuer)

4 - Biofrontera Inc. (0001858685) (Issuer)

4 - Biofrontera Inc. (0001858685) (Issuer)

4 - Biofrontera Inc. (0001858685) (Issuer)

4 - Biofrontera Inc. (0001858685) (Issuer)

4 - Biofrontera Inc. (0001858685) (Issuer)

3 - Biofrontera Inc. (0001858685) (Issuer)

4 - Biofrontera Inc. (0001858685) (Issuer)

4 - Biofrontera Inc. (0001858685) (Issuer)

 ●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton.    ●Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or 5.6% as compared to the same period last year. Without the impact of Hurricane Milton delaying shipments, the increase would have been 12%.    ●Ameluz® achieved record volume in September 2024.      ●Organization continues to prudently manage SG&A expenses in line with business needs with a reduction of 14% in the first 9 months of 2024 vs 2023.    ●Cash and cash equivalents were $2.9 million as of September 30, 2

WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.Conference Call and Webcast InformationEvent:Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference CallDate:Thursday, November 14, 2024Time:10:00am ETConference Call:1-877-

Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months ended June 30, 2024 and provided a business update. Highlights from the second quarter of 2024 and subsequent weeks included the following: Total revenues for the second quarter of 2024 were $7.8 million, a 34% increase from the same period of the prior yearCash and cash equivalents were $4.4 million as of June 30, 2024, compared with $1.3 million on December 31, 2023Biofrontera announced the launch of a new, FDA-approved red-light sour

WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2024 on Wednesday, August 14, 2024. The results will be released after the market close on Wednesday, Aug 14 and the company will host a conference call on Thursday, August 15 at 10:00am Eastern Time.Conference Call and Webcast InformationEventBiofrontera Inc. Second Quarter 2024 Financial Results and Business Update Conference CallDateThursday, August 15, 2024Time10:00am ETConference Call1-877-877-1275 (U.S.)1-412-858-5202 (international)W

Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2024 and provided a business update.Highlights from the first quarter of 2024 and subsequent weeks included the following:Total revenues for the first quarter of 2024 were $7.9 million, a 9% decrease from the same period of the prior year primarily driven by reimbursement headwinds our customers experienced due to the Change Healthcare data breachCash and cash equivalent

WOBURN, MA / ACCESSWIRE / May 6, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three months ended March 29, 2024 on Wednesday, May 15, 2024. The results will be released after the market close on Wednesday, May 15 and the company will host a conference call on Thursday, May 16 at 10:00am Eastern Time.Conference Call and Webcast InformationToll Free1-877-877-1275International1-412-858-5202WebcastWebcast | Biofrontera Inc. First Quarter 2024 Financial Results and Business Update Conference Call (choruscall.com)About Biofrontera Inc.Biofrontera Inc

Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2023.Highlights from 2023 and subsequent weeks include:Record total revenues of $34.1M reported for 2023, an increase of 19% over total revenues for 2022 of $28.7M.Total operating expenses for the year were $56.7 million compared with $47.3 million for 2022. Approximately, $2.0M of this increase was driven by one-time legal expenses.Achieved 4% increase

Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2023.Highlights from 2023 and subsequent weeks include:Record total revenues of $34.1M reported for 2023, an increase of 19% over total revenues for 2022 of $28.7M.Total operating expenses for the year were $56.7 million compared with $47.3 million for 2022. Approximately, $2.0M of this increase was driven by one-time legal expenses.Achieved 4% increase

WOBURN, MA / ACCESSWIRE / January 11, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenues for the three and twelve months ended December 31, 2023.Biofrontera achieved 2023 revenue of approximately $33.8 million to $34.3 million, a record high and up approximately 19% growth compared with 2022. Revenues for the fourth quarter of 2023 are anticipated to be in the range of approximately $10.4 million to $10.9 million, an increase of approximately 5% compared with the fourth quarter of 2022. After a slow start in the first quarter of the year, Biofrontera grew revenues

WOBURN, MA / ACCESSWIRE / November 3, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2023, after the close of the U.S. financial markets on Thursday, November 9, 2023. The Company will hold a conference call on Friday, November 10, 2023 beginning at 10:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.Conference Call and Webcast InformationEvent:Biofrontera Inc. Third Quarter 2023 Financial Results and Business Update Conference CallDate:Friday, November 10, 2023Time:10:00